Patent ID: 6583156
Filing Date: 2003-06-24
Classification: A61K,C07D

Abstract:
A method of treating or preventing movement disorders, comprising administering to a subject in need thereof an effective amount of a compound of formula I: wherein:R1 is hydrogen or alkyl; R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, aryl and 4, 5, 6, 7 or 8 membered unbridged saturated and partially unsaturated heterocyclic rings containing one or more heteroatoms selected from the group consisting of O, S and N, or together form a 3, 4, 5, 6 or 7 membered saturated or partially-unsaturated carbocyclic ring or a 3, 4, 5, 6, 7 or 8 membered saturated or partially unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of O, S and N; or R1 and R2 or R3 together form a 3, 4, 5, 6, 7 or 8 membered oxygen-containing saturated or partially unsaturated heterocyclic ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S and N; or R1 and R2 and R3 together form a 4, 5, 6, 7 or 8 membered oxygen-containing partially unsaturated or aromatic heterocyclic ring optionally containing one or more additional heteroatoms selected from the group consisting of O, S and N in which R2 and R3 together form a double bond; wherein said carbocyclic ring or said heterocyclic ring when partially unsaturated or aromatic may be fused to an aryl ring; andR4, R5, R6, R7, R8 and R9 are independently selected from the group consisting of hydrogen, alkyl; aryll 4, 5, 6, 7 or 8 membered saturated and partially unsaturated heterocyclic rings containing one or more heteroatoms selected from the group consisting of O, S, and N; hydroxy; halogen, nitro, cyano, alkoxy, aryloxy, COR10, OCOR10, CO2R10, SR10, SOR10, SO2R10, SO2NR10R11, CONR10R11, CONR10NR11R12, OCONR10R11, NR10R11, NR10COR11, NR10CONR11R12, NR10CO2R11, NR10SO2R11, CR10NOR11, NR10CONR11NR12R13, NR10NR11CO2R12, NR10NR11CONR12R13, NR10NR11COR12, NR10NR11SO2R12, SO2NR10NR11R12, NR10SO2NR11NR12R13 and NR10SO2NR11R12, wherein R10, R11, R12 and R13 are independently selected from the group consisting of hydrogen, alkyl and aryl, or a pharmaceutically acceptable salt or prodrug thereof; other than (â€”)-(11S,2â€²R)-&agr;-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol, with the proviso that where R1 and R4 to R9 are hydrogen, R2 or R3 is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl.